{"entity":{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","aka":["LYNK-002"],"tldr":"A phase 2 trial of Olaparib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) is a phase 2 interventional study registered as NCT03742895 by Merck Sharp & Dohme LLC, with 329 participants enrolled, started 2018-12-12 and due to reach its primary completion in 2025-08-12. Interventions recorded: Olaparib. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03742895","url":"https://clinicaltrials.gov/study/NCT03742895"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":["merck","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03742895","phase":"2","setting":"A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer","sponsor":"Merck Sharp & Dohme LLC","started":"2018-12-12","startedType":"actual","yearReported":2026,"enrolled":329,"enrolledBasis":"registry","outcomes":[{"endpoint":"Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1","primary":true,"unit":"%","arms":[{"name":"Cohort 1: BRCA1/2 Mutated","n":86,"value":16.3,"note":"95% CI 9.2 to 25.8; Figures from the ClinicalTrials.gov results section (first posted 2026-08-14), not from a publication"},{"name":"Cohort 2: HRD+, HRR Non-mutated","n":90,"value":8.9,"note":"95% CI 3.9 to 16.8"},{"name":"Cohort 2: HRRm, BRCA1/2 Non-mutated","n":140,"value":8.6,"note":"95% CI 4.5 to 14.5"},{"name":"Cohort 3: sBRCAm Breast Cancer","n":7,"value":28.6,"note":"95% CI 3.7 to 71.0"}],"source":"https://clinicaltrials.gov/study/NCT03742895?tab=results"}]},"route":"/trials/nct03742895/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}